GSM城市站国家站国际

FDA批准giredestrant联合依维莫司治疗ESR1突变晚期乳腺癌

2026-11-16 · 联邦 · GSM News
FDA批准giredestrant联合依维莫司治疗ESR1突变晚期乳腺癌

美国食品药品监管局(FDA)11月16日批准 giredestrant(商品名 Wilserdly,Genentech 公司)联合依维莫司用药,用于治疗一类局部晚期或转移性乳腺癌成人患者。

FDA 公布的批准信息写明,适用患者须经 FDA 授权的检测确认肿瘤为雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性、雌激素受体1(ESR1)突变;且病情须是在完成内分泌辅助治疗期间或之后复发,或在转移阶段接受过至少一种内分泌治疗方案后进展。giredestrant 是一种口服雌激素受体拮抗剂,本次批准为联合依维莫司的组合用法。

该批准列入 FDA 肿瘤与血液恶性肿瘤批准通知,发布日期为11月16日。(来源:美国食品药品监管局)

FDA Approves Giredestrant in Combination With Everolimus for ESR1-Mutated Advanced Breast Cancer

On November 16, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly, Genentech, Inc.) in combination with everolimus for the treatment of adults with a defined type of locally advanced or metastatic breast cancer.

According to the FDA approval notice, eligible patients must have estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated disease, as detected by an FDA-authorized test, and their disease must have recurred during or after completion of endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting. Giredestrant is an oral estrogen receptor antagonist, and the approval covers its use in combination with everolimus.

The approval was listed in the FDA's oncology and hematologic malignancies approval notifications dated November 16. (Source: U.S. Food and Drug Administration)

来源:美国食品药品监管局

发布:GSM·美国(发布链接)

图片来源:图:美国食品药品监管局(FDA)总部大楼入口(门楣标示 FOOD AND DRUG ADMINISTRATION)。FDA 官方图,公共领域,经 Wikimedia Commons,本站联邦图库固定图、本篇裁切变体。 / Photo: Entrance of U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons; GSM federal asset library, cropped variant for this story.

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

← 返回联邦 全部新闻 关于我们

GSM首页白宫联邦加州南加各州社会军事司法选举世界中国城市站国家站移民宣传专题视频直播放映厅电子书电子报科技金融教育医疗影视音乐体育文旅时尚演出活动娱乐游戏生活美食户外交通汽车地产保险儿童长者留学生宠物信仰非盈利机构